HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 2, 2026 is 3.97 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 5.40 % — a change of -26.41% (lower).

EBIT/Assets

3.97 %

YoY

-26.41%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of HaTay Pharmaceutical JSC is 2024 3.97 % . Operating Income to Assets Ratio (EBIT/Assets) of HaTay Pharmaceutical JSC was 2023 5.40 % . It decreases by -26.41% lower compared to the previous year.

The HaTay Pharmaceutical JSC EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2017
13.45 VND
Jan 1, 2018
13.84 VND
Jan 1, 2019
13.30 VND
Jan 1, 2020
11.89 VND
Jan 1, 2021
5.02 VND
Jan 1, 2022
6.97 VND
Jan 1, 2023
5.40 VND
Jan 1, 2024
3.97 VND
The HaTay Pharmaceutical JSC EBIT/Assets history
YEAREBIT/AssetsYoY
3.97 %-26.41%
5.40 %-22.58%
6.97 %+39.01%
5.02 %-57.83%
11.89 %-10.56%
13.30 %-3.93%
13.84 %+2.94%
13.45 %+4.81%
12.83 %+18.37%
10.84 %+1.47%
10.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

Operating Income to Assets Ratio (EBIT/Assets) of HaTay Pharmaceutical JSC is 3.97 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of HaTay Pharmaceutical JSC changed from 5.40 % to 3.97 %, representing a -26.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s HaTay Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — HaTay Pharmaceutical JSC

All Key Metrics — HaTay Pharmaceutical JSC